



INTERNATIONAL WORKSHOP ON MONOCLONAL ANTIBODIES

FOR TREATMENT & PREVENTION OF INFECTIOUS DISEASES 2023

HYBRID | 18 APRIL 2023 | COPENHAGEN, DENMARK



PROGRAM CHAIRS

Charles Flexner
MD

Johns Hopkins University
School of Medicine,
United States

Daniel Kuritzkes
MD

Brigham and Women's
Hospital; Harvard Medical
School,
United States



ABOUT THE WORKSHOP

With more than 100 monoclonal antibodies (mAbs) in use, harnessing this technology has advanced therapeutic development for COVID-19 and underscored their utility and versatility to respond rapidly to emerging global health threats.

Recent approvals and recommendations for mAbs in preventing and treating RSV and Ebola offer novel tools to control these (re) emerging viruses.

They also offer new avenues for preventing bacterial and parasitic infections, such as *Clostridium difficile* and *Plasmodium falciparum* (causative agent of malaria tropica in humans).

Those advances come hand-in-hand with educational needs to comprehend technology, pharmacological properties, challenges for equitable access, and recent clinical data.

In contrast to existing programs, this workshop provides a platform for cross-disciplinary discussion, catalyzing knowledge transfer and prompting the discussions on remaining unknowns to ultimately move the field forward.

Register Here



<http://bit.ly/3XC5J0M>



REGISTRATION IS NOW OPEN

We are delighted to announce that registration is open for the second International Workshop on Monoclonal Antibodies for Treatment & Prevention of Infectious Diseases!

This year, **this exciting event will be held in a hybrid format (just after ECCMID) on 18 April in Copenhagen, Denmark.**

Registration fees are waived for healthcare professionals - act fast to secure your place!

REGISTER NOW!



<http://bit.ly/3XC5JOM>

PROGRAM PREVIEW

The program is being developed by some of the field's key experts and topics for exploration include:

- Prevention of Recurrent *Clostridium difficile* Infection
- Prevention of RSV in Neonates
- How Monoclonal Antibodies Shape the Therapeutic Landscape for Neglected Diseases (Malaria and Ebola)
- Monoclonal Antibodies for HIV—Lessons Learned from COVID-19

ORGANIZING COMMITTEE



Marina Caskey MD
The Rockefeller University,
United States



Charles Flexner MD
Johns Hopkins University
School of Medicine,
United States



Daniel Kuritzkes MD
Brigham and Women's
Hospital; Harvard Medical
School,
United States



Anton Pozniak MD, FRCP
Chelsea and Westminster
Hospital,
United Kingdom



Jonathan Schapiro MD
National Hemophilia Center,
Sheba Medical Center,
Israel

ACKNOWLEDGMENT

CONTRIBUTOR LEVEL



FOR MORE INFORMATION VISIT WWW.ACADEMICMEDICALEDUCATION.COM